On December 31, 2019, the local authorities of Wuhan, Hubei province, China, reported a cluster of pneumonia cases of unknown origin. On January 9, 2020, the China Centre for Disease Control reported a novel Coronavirus (2019-nCoV) to be the causative agent.
Recalling the SARS-CoV epidemic in 2003 with over 8000 cases reported (10% case fatality), it is crucial to rapidly gain a better understanding of the newly identified virus, especially in relation to potential clinical and public health measures that can be put to immediate use to improve patients’ health and/or contain the spread of 2019-nCoV.
Proposals submitted under this expression of interest are expected to advance the knowledge on 2019-nCoV and its impact on infected persons, with the aim of contributing to an efficient patient management and/or public health preparedness and response. Proposals must be timely, with rapid activation, to enable early and valuable outcomes to be established. For increased impact, proposals may wish to build on promising avenues from previous or ongoing research.
Considering that this is a newly identified virus, the scope of this expression of interest remains broad and may include topics such as development of therapeutics and point of care diagnostics, clinical and epidemiological studies and social sciences research.
The GloPID-R Secretariat is a project which receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874667.